Related Experiment Video

Updated: Jul 11, 2026

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

[Metabolic bone disease in premature infants and genetic polymorphisms]

Simone Funke1, Eva Morava, Márta Czakó

  • 1Pécsi Tudományegyetem, Altalános Orvostudományi Kar Szülészeti és Nogyógyászati Klinika Pécs Edesanyák útja 17. 7624. Simone.funke@aok.pte.hu

Orvosi Hetilap
|October 9, 2007
PubMed

Insights

Genetic factors like estrogen receptor gene polymorphisms may increase the risk of metabolic bone disease in very-low-birth-weight infants. These findings highlight potential genetic links to bone health in premature babies.

Area of Science:

  • Pediatric Endocrinology
  • Genetics
  • Bone Metabolism

Background:

  • Metabolic bone disease is a significant complication in very-low-birth-weight (VLBW) infants.
  • Osteoporosis in adults is linked to polymorphisms in vitamin D receptor, estrogen receptor, and collagen Ialpha1 receptor genes.

Purpose of the Study:

  • To investigate the association between metabolic bone disease in VLBW infants and allelic polymorphisms of the vitamin D receptor, estrogen receptor, and collagen Ialpha1 receptor genes.

Main Methods:

  • 104 VLBW infants were enrolled.
  • Bone formation and resorption markers were measured.
  • Radiological assessments of bone health were performed.

Main Results:

  • Metabolic bone disease was diagnosed in 28.8% of infants.
  • A significant correlation was found between the estrogen receptor gene's (TA)n allelic variant and bone disease, with fewer repeats associated with higher risk.
  • Interactions between vitamin D receptor and collagen Ialpha1 receptor genotypes were significant.
  • Male gender, longer hospitalization, and specific estrogen receptor genotypes correlated with bone disorder.

Conclusions:

  • Genetic polymorphisms, particularly in the estrogen receptor gene, may be associated with the development of metabolic bone disease in VLBW infants.
  • Further research into genetic predispositions for bone disorders in premature infants is warranted.
Abstract

More Related Videos

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts07:56

Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts

Published on: January 29, 2018

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics09:43

Using Real-Time Cell Metabolic Flux Analyzer to Monitor Osteoblast Bioenergetics

Published on: March 1, 2022

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Bone Disorders01:29

Bone Disorders

Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...